IBDEI0YJ ; ; 12-AUG-2014
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;MAY 15, 2014
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,17161,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,17161,1,1,0)
 ;;=1^280.0
 ;;^UTILITY(U,$J,358.3,17161,1,8,0)
 ;;=8^Iron Def Anemia,d/t Blood Loss Anemia
 ;;^UTILITY(U,$J,358.3,17161,2)
 ;;=^267971
 ;;^UTILITY(U,$J,358.3,17162,0)
 ;;=280.1^^111^1075^28
 ;;^UTILITY(U,$J,358.3,17162,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,17162,1,1,0)
 ;;=1^280.1
 ;;^UTILITY(U,$J,358.3,17162,1,8,0)
 ;;=8^Iron Def Anemia,d/t Dietary Intake
 ;;^UTILITY(U,$J,358.3,17162,2)
 ;;=^267972
 ;;^UTILITY(U,$J,358.3,17163,0)
 ;;=280.8^^111^1075^26
 ;;^UTILITY(U,$J,358.3,17163,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,17163,1,1,0)
 ;;=1^280.8
 ;;^UTILITY(U,$J,358.3,17163,1,8,0)
 ;;=8^Iron Def Anemia,Oth Spec
 ;;^UTILITY(U,$J,358.3,17163,2)
 ;;=^88088
 ;;^UTILITY(U,$J,358.3,17164,0)
 ;;=284.09^^111^1075^13
 ;;^UTILITY(U,$J,358.3,17164,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,17164,1,1,0)
 ;;=1^284.09
 ;;^UTILITY(U,$J,358.3,17164,1,8,0)
 ;;=8^Constitutional Aplastic Anemia,Oth
 ;;^UTILITY(U,$J,358.3,17164,2)
 ;;=^334036
 ;;^UTILITY(U,$J,358.3,17165,0)
 ;;=286.9^^111^1076^9
 ;;^UTILITY(U,$J,358.3,17165,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,17165,1,1,0)
 ;;=1^286.9
 ;;^UTILITY(U,$J,358.3,17165,1,8,0)
 ;;=8^Defective Coagulation,Unspec
 ;;^UTILITY(U,$J,358.3,17165,2)
 ;;=^87267
 ;;^UTILITY(U,$J,358.3,17166,0)
 ;;=446.6^^111^1076^26
 ;;^UTILITY(U,$J,358.3,17166,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,17166,1,1,0)
 ;;=1^446.6
 ;;^UTILITY(U,$J,358.3,17166,1,8,0)
 ;;=8^Thrombotic Microangiopathy
 ;;^UTILITY(U,$J,358.3,17166,2)
 ;;=^119061
 ;;^UTILITY(U,$J,358.3,17167,0)
 ;;=451.9^^111^1076^25
 ;;^UTILITY(U,$J,358.3,17167,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,17167,1,1,0)
 ;;=1^451.9
 ;;^UTILITY(U,$J,358.3,17167,1,8,0)
 ;;=8^Thrombophlebitis
 ;;^UTILITY(U,$J,358.3,17167,2)
 ;;=^93357
 ;;^UTILITY(U,$J,358.3,17168,0)
 ;;=287.5^^111^1076^23
 ;;^UTILITY(U,$J,358.3,17168,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,17168,1,1,0)
 ;;=1^287.5
 ;;^UTILITY(U,$J,358.3,17168,1,8,0)
 ;;=8^Thrombocytopenia Nos
 ;;^UTILITY(U,$J,358.3,17168,2)
 ;;=^118988
 ;;^UTILITY(U,$J,358.3,17169,0)
 ;;=287.30^^111^1076^21
 ;;^UTILITY(U,$J,358.3,17169,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,17169,1,1,0)
 ;;=1^287.30
 ;;^UTILITY(U,$J,358.3,17169,1,8,0)
 ;;=8^Primary Thrombocytopenia (ITP)
 ;;^UTILITY(U,$J,358.3,17169,2)
 ;;=^332841
 ;;^UTILITY(U,$J,358.3,17170,0)
 ;;=238.71^^111^1076^24
 ;;^UTILITY(U,$J,358.3,17170,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,17170,1,1,0)
 ;;=1^238.71
 ;;^UTILITY(U,$J,358.3,17170,1,8,0)
 ;;=8^Thrombocytosis,Essential
 ;;^UTILITY(U,$J,358.3,17170,2)
 ;;=^334027
 ;;^UTILITY(U,$J,358.3,17171,0)
 ;;=286.53^^111^1076^4
 ;;^UTILITY(U,$J,358.3,17171,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,17171,1,1,0)
 ;;=1^286.53
 ;;^UTILITY(U,$J,358.3,17171,1,8,0)
 ;;=8^Antiphospholipid w/ Hemor d/o
 ;;^UTILITY(U,$J,358.3,17171,2)
 ;;=^340503
 ;;^UTILITY(U,$J,358.3,17172,0)
 ;;=286.0^^111^1076^7
 ;;^UTILITY(U,$J,358.3,17172,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,17172,1,1,0)
 ;;=1^286.0
 ;;^UTILITY(U,$J,358.3,17172,1,8,0)
 ;;=8^Congenital Factor VII Disorder
 ;;^UTILITY(U,$J,358.3,17172,2)
 ;;=^27454
 ;;^UTILITY(U,$J,358.3,17173,0)
 ;;=286.1^^111^1076^5
 ;;^UTILITY(U,$J,358.3,17173,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,17173,1,1,0)
 ;;=1^286.1
 ;;^UTILITY(U,$J,358.3,17173,1,8,0)
 ;;=8^Cogenital Factor IX Disorder
 ;;^UTILITY(U,$J,358.3,17173,2)
 ;;=^27452
 ;;^UTILITY(U,$J,358.3,17174,0)
 ;;=286.2^^111^1076^8
 ;;^UTILITY(U,$J,358.3,17174,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,17174,1,1,0)
 ;;=1^286.2
